18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To confirm the diagnostic effectiveness of 18F-Fluorodeoxyglucose(FDG) as compared to the gold standard of histopathological diagnosis.
The primary outcomes of sensitivity and accuracy of 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) studies will be obtained by comparing results of the PET scan with the gold standard of histopathological diagnosis when those results are available. Comparison to correlative imaging follow-up, and assessment of efficacy based on feedback from referring physicians will be used in the absence of pathologic data.
Three years
No
Daniel P Levin, BSc,MD,FRCPC
Principal Investigator
Winnipeg Regional Health Authority
Canada: Health Canada
B2010:014
NCT01180751
July 2010
April 2013
Name | Location |
---|